This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Matt Cohen
Partner at Osage University Partners


Matt joined OUP in 2013 and focuses on investments in therapeutics, diagnostics, medical devices, and research tools. He has been involved with OUP’s investment in several portfolio companies including Kura Oncology (NASDAQ: KURA), Cell Design Labs (acquired by Gilead), Biohaven Pharma (NYSE: BHVN), Arrakis Therapeutics, PMV Pharma, and others. Prior to joining OUP, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma, diagnostics, research tools, healthcare, and private equity.
Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from The Pennsylvania State University.

Agenda Sessions

  • Panel Discussion: Investment in the CGT space: trends, technologies and early stage success